

SIX-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB IN PATIENTS WITH PATHOLOGIC MYOPIA

Retina

37, 1055-1064

DOI: 10.1097/iae.0000000000001313

Citation Report

#	ARTICLE	IF	CITATIONS
1	Progression of Myopic Maculopathy during 18-Year Follow-up. <i>Ophthalmology</i> , 2018, 125, 863-877.	2.5	158
2	Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia. <i>Ophthalmologica</i> , 2018, 239, 133-142.	1.0	5
3	Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. <i>Progress in Retinal and Eye Research</i> , 2018, 63, 92-106.	7.3	125
4	EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE. <i>Retina</i> , 2018, 38, 1464-1477.	1.0	99
5	Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization. <i>Scientific Reports</i> , 2018, 8, 14389.	1.6	8
6	Neun-Jahres-Ergebnisse zur Ranibizumab-Monotherapie der choroidalen Neovaskularisation infolge pathologischer Myopie. <i>Karger Kompass Ophthalmologie</i> , 2018, , 122-131.	0.0	0
7	Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan. <i>Eye</i> , 2018, 32, 1871-1878.	1.1	10
8	Possible connection of short posterior ciliary arteries to choroidal neovascularisations in eyes with pathologic myopia. <i>British Journal of Ophthalmology</i> , 2019, 103, 457-462.	2.1	36
9	FIVE-YEAR OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA. <i>Retina</i> , 2019, 39, 1289-1298.	1.0	24
10	Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the MYRROR study. <i>Acta Ophthalmologica</i> , 2019, 97, e729-e735.	0.6	6
11	Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 749-757.	1.0	13
12	Diagnosis and Treatment of Myopic Maculopathy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019, 7, 415-421.	1.3	17
13	Updates on Myopia. , 2020, , .		16
14	Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia. <i>International Ophthalmology</i> , 2020, 40, 833-839.	0.6	1
15	Ranibizumab for myopic choroidal neovascularization. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1385-1393.	1.4	14
16	Accuracy of a deep convolutional neural network in the detection of myopic macular diseases using swept-source optical coherence tomography. <i>PLoS ONE</i> , 2020, 15, e0227240.	1.1	32
17	Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China. <i>BMC Ophthalmology</i> , 2021, 21, 116.	0.6	4
18	Dilated choroidal veins and their role in recurrences of myopic macular neovascularisations. <i>British Journal of Ophthalmology</i> , 2022, 106, 1429-1435.	2.1	5

#	ARTICLE	IF	CITATIONS
19	IMI Pathologic Myopia. , 2021, 62, 5.		140
20	Using optical coherence tomography angiography to guide myopic choroidal neovascularization treatment: a 3-year follow-up study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 3295-3303.	1.0	2
21	Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. Expert Opinion on Drug Safety, 2022, 21, 43-54.	1.0	9
22	Prognostic Tomographic Classification of Myopic Choroidal Neovascularization. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 775-779.	0.4	1
23	Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors. Pharmaceuticals, 2021, 14, 1042.	1.7	5
24	Clinical Management of Myopia in Adults: Treatment of Myopic CNV. , 2020, , 271-288.		0
25	Myopic Macular Neovascularization; Treatment Outcome (Including MP3). , 2020, , 69-75.		1
26	Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia. British Journal of Ophthalmology, 2023, 107, 1043-1050.	2.1	8
27	Long-term incidence and risk factors of macular fibrosis, macular atrophy, and macular hole in eyes with myopic neovascularization. Ophthalmology Retina, 2022, , .	1.2	3
28	Characteristics of choroidal neovascularization in elderly eyes with high myopia not meeting the pathologic myopia definition. Scientific Reports, 2022, 12, .	1.6	2
29	RISK FACTORS OF VISION LOSS AND MULTIPLE RECURRENCES IN MYOPIC MACULAR NEOVASCULARIZATION. Retina, 2023, 43, 275-285.	1.0	2
30	LONG-TERM TREATMENT OUTCOMES AFTER BEVACIZUMAB THERAPY FOR MACULAR NEOVASCULARIZATION IN WHITE PATIENTS WITH HIGH MYOPIA. Retina, 2023, 43, 444-453.	1.0	4
31	Myopic macular diseases: A review. Clinical and Experimental Ophthalmology, 2023, 51, 229-242.	1.3	4
33	Characteristics and response of subretinal hyperreflective material to anti-vascular endothelial growth factor in myopic choroidal neovascularization. Scientific Reports, 2023, 13, .	1.6	0